Making a case for outpatient parenteral antimicrobial therapy (OPAT).

Making a case for outpatient parenteral antimicrobial therapy (OPAT).

Publication date: Aug 01, 2024

In the wake of the COVID-19 pandemic, and its negative impact on both acute and elective care and decline in available inpatient resources, there is an imperative to maximize safe and effective alternatives to inpatient hospital care. Properly governed outpatient parenteral antimicrobial therapy (OPAT) services embed the principles of antimicrobial stewardship (AMS) (including use of early oral therapy) and support admission avoidance and early discharge for a growing range of patient groups with complex infections through well-organized multidisciplinary team working. Expansion of OPAT aligns with the UK’s national strategy to deliver care closer to home and cost-effectively maximize use of inpatient resources. OPAT serves as an exemplar to other ambulatory services and presents opportunities for developing and assuring AMS strategies within the rapidly developing hospital-at-home and virtual ward environments.

Concepts Keywords
Covid Ambulatory Care
Expansion Anti-Bacterial Agents
Home Anti-Bacterial Agents
Inpatient Anti-Infective Agents
Pandemic Anti-Infective Agents
Antimicrobial Stewardship
COVID-19
Humans
Infusions, Parenteral
Outpatients
SARS-CoV-2
United Kingdom

Semantics

Type Source Name
disease MESH COVID-19 pandemic
disease VO effective
disease MESH infections

Original Article

(Visited 2 times, 1 visits today)